1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

03 May 2024
Admin
News Article

Galecto Starts Phase 2 Trial by dosing in Investigator-Initiated Study Combining GB1211

Galecto Starts Phase 2 Trial with First Patient Dosed in Investigator-Initiated Study Combining GB1211 and Pembrolizumab

Overview

Galecto, Inc. (NASDAQ: GLTO), a biotech company specializing in pioneering cancer and fibrosis treatments, has reached a significant milestone in its clinical journey. They've initiated an investigator-led Phase 2 trial at the Earle A. Chiles Research Institute (EACRI), part of the Providence Cancer Institute in Portland, Oregon, USA. Led by Dr. Brendan Curti and Dr. William Redmond, the trial will evaluate GB1211, Galecto’s oral galectin-3 inhibitor, in combination with pembrolizumab for treating metastatic malignant melanoma (MM) and head and neck squamous cell carcinoma (HNSCC). Supported by a grant from the National Cancer Institute, Galecto is supplying GB1211 for the trial.

The trial stems from galectin-3's overexpression in various cancers, including melanoma and HNSCC, which correlates with tumor progression and resistance to treatments like pembrolizumab and atezolizumab. GB1211 aims to mitigate these resistance mechanisms by inhibiting galectin-3.

Building upon promising Phase 1b/2a trial results, Galecto aims to explore GB1211's potential in combination with pembrolizumab further. Dr. Curti emphasizes the strength of Providence Cancer Institute's research approach, citing insights from Dr. Redmond’s lab as crucial for this trial.

Dr. Redmond highlights their research into galectin-3's role in tumor immune suppression, expressing enthusiasm for countering ICI resistance with GB1211 and pembrolizumab.

Galecto's CEO, Dr. Hans Schambye, lauds the trial's initiation at Providence Cancer Institute, recognizing Dr. Redmond's expertise and anticipating synergistic benefits from combining GB1211 with pembrolizumab.

Phase 2 Trial

The Phase 2 trial, a randomized, double-blind placebo-controlled endeavor, aims to evaluate GB1211's impact on pembrolizumab's response rate in metastatic melanoma and HNSCC patients.
With a focus on assessing both safety and efficacy, the trial will also gather biospecimens to delve into immunological markers relevant to galectin biology and T-cell checkpoint inhibition, with early data anticipated as soon as 2025.

GB1211's Mechanism

GB1211's mechanism, designed to counteract galectin-3's adverse effects, has shown promise in preclinical models and Phase 1 trials, positioning it as a potential game-changer in cancer therapy.
Through collaborative efforts like this trial, Galecto aims to advance innovative treatments and improve patient outcomes in cancer and fibrosis.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!